Abstract: The present invention relates to the combination of the 3-hydroxy-3-methylglutaryl-coenzyme A inhibitor (HMG-CoA inhibitor) cerivastatin with fibrates and its use in the prophylaxis and treatment of disorders of lipid metabolism.

Abstract: Antimicotically active 2-aminothiazoles have been found having the formula ##STR1## in which R.sup.1 represents hydrogen or alkyl andR.sup.2 represents optionally substituted cyclohexyl or phenyl which is substituted by halogen, alkyl, halogenoalkyl, halogenoalkoxy, dioxyhalogenoalkyl or halogenoalkylthio,and their physiologically tolerable acid addition salts,with the exception of the compounds 4-(4-chlorophenyl)-2-[2-(1,4,5,6-tetrahydropyrimidinyl)-amino]thiazole and 4-(2,4-dichlorophenyl)-2-[2-(1,4,5,6-tetrahydropyrimidinyl)-amino]-thiazol e and 4-(4-chloro-2-methylphenyl)-2-[2-(1,4,5,6-tetrahydropyrimidinyl)-amino]-th iazole and with the exception of the physiologically tolerable acid addition salts of these compoundshave been found.

Abstract: A 2-aminothiazole of the formula ##STR1## in which R.sup.1 represents hydrogen or alkyl andR.sup.2 represents a radical of the formula ##STR2## where R.sup.3, R.sup.4, R.sup.5 and R.sup.6 independently of one another in each case represent hydrogen, halogen, nitro, alkyl, alkoxy, alkoxycarbonyl, dialkylamino, alkylthio, alkylsulphinyl, alkylsulphonyl, halogenoalkyl, halogenoalkoxy, halogenoalkylthio, halogenoalkylsulphinyl or halogenoalkylsulphonyl,X represents oxygen, sulphur, sulphinyl or sulphonyl andAr represents an unsubstituted aryl or a substituted aryl radical,and their physiologically tolerable acid addition salts.

Abstract: The invention relates to guanidinothiazol derivatives of Formula (I) as defined herein, said compounds being useful for influencing lipid metabolism, as antithombotic agents and as antimycotic agents. Also included in the invention are compositions containing said guanidinothiazol derivatives of Formula (I) and the use of said compounds and compositions for treatment of the above-mentioned conditions. In addition, the invention includes methods for the manufacture of the guanidinothiazole derivatives of Formula (I).

Abstract: Cyclically substituted fulvalenophanes of the formula ##STR1## where X is S, Se or Te, R is H or lower alkyl, A is --(CH.sub.2).sub.n --and Z is a radical of the formula ##STR2## a p-phenylene radical or a quinodimethane radical of the formula ##STR3## where the radicals R.sup.2 and R.sup.3 are halogen, carboxylic acid ester groups or cyano and R.sup.3 may also be hydrogen, and the quinodimethane ring may be substituted by halogen, nitro or cyano.